A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies

Cancer Immunology, Immunotherapy

Volumn 59, Issue 2, 2010, Pages 257-265

  Cardarelli, Pina M ^a   Rao Naik, Chetana ^a   Chen, Sharline ^a   Huang, Haichun ^a   Pham, Amie ^a   Moldovan Loomis, Maria Cristina ^a   Pan, Chin ^a   Preston, Ben ^a   Passmore, David ^a   Liu, Jie ^a   Kuhne, Michelle R ^a   Witte, Alison ^a   Blanset, Diann ^a   King, David J ^b  

^a Medarex ^*  (United States)

^b AnaptysBio Inc   (United States)

Author keywords

ADCC; B cell lymphoma; CD19; Fc RIIIa; Therapeutic antibodies

Indexed keywords

CD16 ANTIGEN; CD19 ANTIBODY; FUCOSYLTRANSFERASE; MDX 1342; PHENYLALANINE; RITUXIMAB; UNCLASSIFIED DRUG; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; CANCER SURVIVAL; CELL ACTIVITY; CELL FUNCTION; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; EFFECTOR CELL; FUCOSYLATION; IN VIVO STUDY; MONKEY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, CD19; B-LYMPHOCYTES; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOMA, B-CELL; MACACA FASCICULARIS; MICE; MICE, SCID; MICE, TRANSGENIC; PHAGOCYTOSIS; RECEPTORS, IGG; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71849117814     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0746-z     Document Type: Article

References (36)

1. JCW Edwards G Cambridge 2006 B-cell targeting in rheumatoid arthritis and other autoimmune diseases Nat Rev Immunol 6 394 403 10.1038/nri1838 1:CAS:528:DC%2BD28XjslOhu7g%3D 16622478
2. TF Tedder A Baras Y Xiu 2006 Fc receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity Springer Semin Immunol 28 351 364 10.1007/s00281-006-0057-9 1:CAS:528:DC%2BD28Xht1Kgt77O (Pubitemid 44900574)
3. A Molina 2008 A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma Annu Rev Med 59 237 250 10.1146/annurev.med.59.060906. 220345 1:CAS:528:DC%2BD1cXis12nur4%3D 18186705 (Pubitemid 351291630)
4. V Vidal A Gafter-Gvili L Leibovici, et al. 2009 Rituximab maintenance for the treatment of patients with follicular lymphoma: systemic review and meta-analysis of randomized trial J Natl Cancer Inst 2009 101 248 255
5. Jacobi AM, Mei H, Hoyer BF et al (2009) HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with SLE. Ann Rheum Dis Feb 5 Epub
6. A Hekman A Honselaar WMJ Vuist, et al. 1991 Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody Cancer Immunol Immunother 32 364 372 10.1007/BF01741331 1:STN:280:DyaK3M7ns1CrsQ%3D%3D 1706642
7. LT Vlasveld A Hekman FA Vyth-Dreese, et al. 1995 Treatment of low grade non-Hodgkins lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B cell specific monoclonal antibody CLB-CD19 Cancer Immunol Immunother 40 37 47 1:STN:280:DyaK2M7ivFSktA%3D%3D 7530170
8. AJ Rowland GA Pietersz IF McKenzie 1993 Preclinical investigation of the antitumor effects of anti-CD19 idarubicin immunoconjugates Cancer Immunol Immunother 37 195 202 10.1007/BF01525435 1:CAS:528:DyaK2cXhvVanu7s%3D 7687521
9. RVJ Chari KA Jackel LA Bourret, et al. 1995 Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation Cancer Res 55 4079 4084 1:CAS:528:DyaK2MXotV2mtrY%3D 7545085
10. J Bruenke K Barbin S Kunert, et al. 2005 Effective lysis of lymphoma cells with a stabilized bispecific single-chain Fv antibody against CD19 and FcγRIII (CD16) Br J Haematol 130 218 228 10.1111/j.1365-2141.2005.05414.x 1:CAS:528:DC%2BD2MXpt1Cjsbc%3D 16029450 (Pubitemid 41602522)
11. M Molhoj S Crommer K Brischwein, et al. 2007 CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis Mol Immunol 44 1935 1943 10.1016/j.molimm.2006.09. 032 1:CAS:528:DC%2BD28Xht1Kitb3N 17083975 (Pubitemid 44827259)
12. R Bargou E Loe G Zugmaier, et al. 2008 Tumor regression in cancer patients by very low doses of a T-cell engaging antibody Science 321 974 977 10.1126/science.1158545 1:CAS:528:DC%2BD1cXpslWru70%3D 18703743
13. RA Clynes TL Towers LG Presta, et al. 2000 Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 443 446 10.1038/74704 1:CAS:528:DC%2BD3cXisVOru7Y%3D 10742152 (Pubitemid 30208162)
14. G Cartron L Dacheux G Salles, et al. 2002 Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene Blood 99 745 758 10.1182/blood.V99.3.754 (Pubitemid 34525533)
15. RL Shields AK Namenuk K Hong, et al. 2001 High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R J Biol Chem 276 6591 6604 10.1074/jbc.M009483200 1:CAS:528:DC%2BD3MXhslShurs%3D 11096108
16. GA Lazar W Dang S Karki, et al. 2006 Engineered antibody Fc variants with enhanced effector function Proc Natl Acad Sci USA 103 4005 4010 10.1073/pnas.0508123103 1:CAS:528:DC%2BD28XivFWitLw%3D 16537476
17. P Umana J Jean-Mairet R Moudry, et al. 1999 Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity Nat Biotechnol 17 176 180 10.1038/6179 1:CAS:528:DyaK1MXpsl2ktw%3D%3D 10052355 (Pubitemid 29072543)
18. T Shinkawa K Nakamura N Yamane, et al. 2003 The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity J Biol Chem 278 3466 3473 10.1074/jbc.M210665200 1:CAS:528:DC%2BD3sXmt1Kiuw%3D%3D 12427744 (Pubitemid 36801263)
19. R Niwa E Shoji-Hosaka M Sakurada, et al. 2004 Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma Cancer Res 64 2127 2133 10.1158/0008-5472.CAN-03-2068 1:CAS:528: DC%2BD2cXitFCgurs%3D 15026353 (Pubitemid 38339463)
20. HM Horton MJ Bernett E Pong, et al. 2008 Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia Cancer Res 68 8049 8057 10.1158/0008-5472.CAN-08-2268 1:CAS:528:DC%2BD1cXhtF2msLrF 18829563
21. C Ferrara F Stuart P Sondermann, et al. 2006 The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to nonfucosylated IgG glycoforms J Biol Chem 281 5032 5036 10.1074/jbc.M510171200 1:CAS:528:DC%2BD28Xhs1ektrs%3D 16330541 (Pubitemid 43847767)
22. N Lonberg 2005 Human antibodies from transgenic animals Nat Biotechnol 23 1117 1125 10.1038/nbt1135 1:CAS:528:DC%2BD2MXpvVyrtrw%3D 16151405 (Pubitemid 41486393)
23. N Yamane-Ohnuki S Kinoshita M Inoue-Urakabo, et al. 2004 Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity Biotechnol Bioeng 97 614 622 10.1002/bit.20151 (Pubitemid 39295406)
24. R Niwa A Natsume A Uehara, et al. 2005 IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides J Immunol Methods 306 151 160 10.1016/j.jim.2005.08.009 1:CAS:528:DC%2BD2MXhtlSjt7%2FK 16219319 (Pubitemid 41739846)
25. PJ Carter 2006 Potent antibody therapeutics by design Nat Rev Immunol 6 343 357 10.1038/nri1837 1:CAS:528:DC%2BD28XjslOhu7o%3D 16622479
26. RL Shields J Lai R Keck, et al. 2002 Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity J Biol Chem 277 26733 26740 10.1074/jbc.M202069200 1:CAS:528:DC%2BD38XlvV2isrk%3D 11986321 (Pubitemid 34951677)
27. P McLaughlin AJ Grillo-Lopez BK Link, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy in patients with relapsed or indolent lymphoma: half of patients respond to a four dose treatment program J Clin Oncol 16 2825 2833 1:CAS:528:DyaK1cXlsFCgu7c%3D 9704735
28. JH Anolik D Campbell RE Felgar, et al. 2003 The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus Arthritis Rheum 48 455 459 10.1002/art.10764 1:CAS:528:DC%2BD3sXhslKktL4%3D 12571855 (Pubitemid 36278014)
29. TA Davis DK Czerwinski R Levy 1999 Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression Clin Cancer Res 5 611 615 1:CAS:528:DyaK1MXitVyisbw%3D 10100713
30. F Nimmerjahn JV Ravetch 2005 Divergent immunoglobulin G subclass activity through selective Fc receptor binding Science 310 1510 1512 10.1126/science.1118948 1:CAS:528:DC%2BD2MXht1GqsrjM 16322460 (Pubitemid 41746349)
31. WK Weng R Levy 2003 Two immunoglobulin G fragment receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J Clin Oncol 21 3940 3947 10.1200/JCO.2003.05.013 1:CAS:528: DC%2BD2cXpsVajsb8%3D 12975461 (Pubitemid 46606207)
32. E Hatjiharissi L Xu DD Sants, et al. 2007 Increased natural killer cell expression of CD16, and augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism Blood 110 2561 2564 10.1182/blood-2007-01-070656 1:CAS:528:DC%2BD2sXhtFCnsbjM 17475906 (Pubitemid 47523179)
33. N Congy-Jolivet A Bolzec D Ternant, et al. 2008 FcγRIIIa expression is not increased on natural killer cells expressing the FcγRIIIa-158 V allotype Cancer Res 68 976 980 10.1158/0008-5472.CAN-07-6523 1:CAS:528:DC%2BD1cXhvFemu7g%3D 18281470 (Pubitemid 351272214)
34. F Nimmerjahn P Bruhns K Horiuchi, et al. 2005 FcγRIV: a novel receptor with distinct IgG subclass specificity Immunity 23 41 51 10.1016/j.immuni.2005.05.010 1:CAS:528:DC%2BD2MXnsVeltrk%3D 16039578 (Pubitemid 41019656)
35. N Yazawa Y Hamaguchi JC Poe, et al. 2005 Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease Proc Natl Acad Sci USA 102 15178 15183 10.1073/pnas. 0505539102 1:CAS:528:DC%2BD2MXhtFGqtb3F 16217038 (Pubitemid 41513355)
36. J Zalevsky IW Leung S Karki, et al. 2009 The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates Blood 113 3735 3743 10.1182/blood-2008-10-182048 1:CAS:528:DC%2BD1MXlt1yjsLs%3D 19109559